Patient-Reported Outcomes and Toxicity Assessment

Dr. Rotow discusses limitations of traditional CTCAE toxicity grading for capturing patient experiences with EGFR-targeted therapies. Although useful for discrete, measurable, and life-threatening toxicities, CTCAE poorly captures lower-grade effects like skin rash or fatigue that significantly impact quality of life over extended treatment periods.

Patient-reported outcomes attempt to bridge this gap by measuring patients' perceived therapy impact on quality of life. Across FLAURA, FLAURA-2, and MARIPOSA studies, PRO data remain relatively stable over time, suggesting treatments don't cause dramatic quality of life deterioration. However, this apparent stability may not capture the fine granularity of patient experiences that clinicians observe in practice.

Dr. Levy emphasizes frequent misalignment between published adverse event data and real-world patient experiences, highlighting the need for meticulous attention to patient-reported symptoms over time. Patients regularly ask about symptom trajectories: immediate post-dose effects, weekly changes, and 6-month projections.

Dr. Lopes advocates for comparing current patient experiences to pre-disease baseline rather than historical chemotherapy toxicities. He describes funding for AI-powered patient-reported outcome tools in immunotherapy research, acknowledging that current quality of life instruments inadequately capture targeted therapy and immunotherapy effects.

The discussion underscores the importance of developing better tools for capturing subjective patient experiences with novel therapies, particularly for treatments administered over extended periods where cumulative lower-grade toxicities may substantially impact quality of life despite appearing manageable in traditional clinical trial metrics.